Bas Groot Koerkamp

TRANSPLANT BENEFIT IN CRLM: OUR PAPER, NOW WITH EDITORIAL INSIGHT Honoured to see our paper in Liver Transplantation, accompanied by an editorial emphasising its importance and practical implications [1]. Our study [2] provides the first real-world external validation of the TransMet trial criteria for unresectable colorectal liver metastases, demonstrating that the survival benefit observed in the trial is reproducible outside the trial setting and quantifying the transplant advantage in a clinically meaningful manner. The editorial emphasises several key points raised by our work: the importance of external validation, the need for refined biological selection, the implications for allocation policy, and the significance of multidisciplinary referral and decision-making in this evolving field. I am grateful to all co-authors and collaborators for their valuable contributions to this significant step forward in transplant oncology. [1]journals.lww.com/lt/fulltext/99… [2]journals.lww.com/lt/fulltext/99… #LiverTransplantation #TransplantOncology #CRLM #TransMet #LiverTransplant #ColorectalLiverMetastases #SurgicalOncology #Research

Neoadjuvant gemcitabine–oxaliplatin, lenvatinib, and anti–PD-1 antibody led to longer event-free survival than surgery alone in resectable high-risk intrahepatic cholangiocarcinoma, with mainly low-grade adverse events. Full phase 2–3 ZSAB-neoGOLP trial results and Research Summary: nejm.org/doi/full/10.10…

We can keep doing prevention trials or simply accept that mitigation is the strategy. Too complex of an anastomosis with too many variables that we cannot control, including interuser variability in technical skill. Antibiotics mitigate carte blanche. pubmed.ncbi.nlm.nih.gov/37940433/

🆕 @ScienceMagazine An exciting new approach vs pancreatic cancer: "cancer interception" Considered ubiquitous, the pancreas in healthy adults has hundreds of PanINs of microscopic premalignant cancer that can be regressed in the experimental model science.org/doi/10.1126/sc… science.org/doi/10.1126/sc…

Could it be this easy? I am not sure to be honest - although it would be nice! Anyone running this trial? Combination of PARP and KRASG12D inhibitors enhances therapeutic efficacy by exploiting vulnerabilities in #PancreaticCancer nature.com/articles/s4146…

🚨Liquid biopsy is trending, and our BTC ctDNA study proves why! published in @JHepatology @myESMO 👉 ctDNA showed 84.8% sensitivity vs. tissue (Tier 1 or 2 mutations) 👉 Novel FGFR2-TNS1 fusion detected 👉 High max VAF predicts poorer Gem/Cis-based chemo outcomes doi.org/10.1016/j.jhep… Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer #BTC #LiquidBiopsy #Blood #ctDNA #CCA

🧬Evolving roles of liquid biopsy in CRC @NatRevClinOncol 👉nature.com/articles/s4157… #cancer #oncology #MedX @OncoAlert

Fall in love with some activity, and do it! Nobody ever figures out what life is all about, and it doesn't matter. Explore the world. Nearly everything is really interesting if you go into it deeply enough. Work as hard and as much as you want to on the things you like to do the best. Don't think about what you want to be, but what you want to do. Keep up some kind of a minimum with other things so that society doesn't stop you from doing anything at all.

Stop. Read this. Here’s what they say about Medicine: Newest versions now re-writing codes to improve itself. Medical analysis. Reading scans, analyzing lab results, suggesting diagnoses, reviewing literature. AI is approaching or exceeding human performance in several areas

Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial. Read the full article. brnw.ch/21wZRWt #pamcsm

In @JCO_ASCO from @valarlabs Development & Validation of a Computational Histology Artificial Intelligence–Powered Predictive Biomarker for Selection of Chemotherapy in Advanced #PancreaticCancer ascopubs.org/doi/10.1200/JC…

Congrats to @curecc mentee Dr. Lara Heij 🇳🇱 on yet another impactful publication in #cholangiocarcinoma @Nature_NPJ #precisiononcology @OHSUKnight nature.com/articles/s4169…

@michael_lidsky from @DukeSurgOnc delivers a fantastic overview on HAI in unresectable CRLM at #ALPS2026

Presenting the final results of the PRIME HCC study, Antonio D’Alessio delivered the first European prospective evidence on neoadjuvant immunotherapy in resectable hepatocellular carcinoma, with deep immune profiling before and after surgery. 💬 “Neoadjuvant trials are a unique window to link immune biology with clinical outcome.”

Presented today at @EASLnews #LiverCancerSummit 2026 #4year OS data from #TOPAZ1 with CisGemDurva for advanced #BTC 👉11.8% of patients alive at 4 years (4.3%) in the placebo arm 🧐subsequent lines of therapy, around 8% targeted - low? reflection of the time when conducted?

Excellent editorial in @JCO_ASCO by @drymtn @OHSUKnight on @BasGrootKoerkam 🇳🇱 PUMP II #HAI ⛽️ #cholangiocarcinoma trial @curecc @CcaEns @PrecisionBTCnet

🤩Day 2 is underway at the EASL #LiverCancerSummit 2026! In a focused and practical presentation, Eric Vibert reviewed how minimally invasive, laparoscopic and robotic approaches are reshaping hepatobiliary cancer resection. ▶️Laparoscopy is an efficient approach in intrahepatic cholangiocarcinoma ▶️Surgery remains indicated for selected HCC, including single tumours larger than 3 cm or up to three nodules smaller than 3 cm ▶️Laparoscopic and robotic techniques facilitate ICG guided surgery and intraoperative precision ▶️Digital twin concepts may help identify complex patients and guide personalised surgical strategies ▶️Robotic surgery is expanding in HPB surgery, but it is still too early to draw firm conclusions @A_DAlessioMD @BasGrootKoerkam @SherrieBhoori @EASLedu

Bruno Sangro at #LiverCancerSummit reviewed the current evidence, unmet needs and future directions for neoadjuvant and adjuvant therapies in hepatocellular carcinoma. ▶️Neoadjuvant and adjuvant strategies in HCC differ fundamentally from other solid tumours due to underlying chronic liver disease and limited resection margins ▶️Biology matters, early stage HCC differs markedly from advanced disease, so benefit cannot be assumed ▶️Key unmet needs include validated pathological response cut offs, predictive biomarkers and phase 3 trials comparing perioperative strategies 💬 “Biology should come before breadth, we need a short window to learn from the tumour, not to treat forever. The liver is the patient and agents must respect hepatic function. Treat the residual risk, not the calendar - MPR/MRD drive adjuvant intensity.” @SherrieBhoori @BasGrootKoerkam

Stefan Schneeberger addressed one of the most persistent challenges in liver cancer care, how to increase access to liver #transplantation. ▶️Organ shortage is not only a technical issue, but one of culture, beliefs, personal choices and resource allocation ▶️Despite stable or improving transplant numbers, mortality on waiting lists remains largely unchanged ▶️Living donor liver transplantation is well established and effective in increasing organ availability ▶️Liver normothermic machine perfusion extends preservation time, improves organ assessment and reduces discard rates ▶️Better utilisation of existing organs may be as important as finding new donors Meaningful progress requires commitment, coordination and willingness to change practice. 💬 “The lack of organs is not just a medical problem, it is a matter of human behaviour and collective responsibility.” @EASLedu @SherrieBhoori @BasGrootKoerkam

Kudos 👏🏽 @LYohanathan for this excellent 📝 #transplantoncology #cholangiocarcinoma #mCRC #HCC @curecc @OHSUKnight